|
Friday, 29 January 2021, 08:00 HKT/SGT | |
| |
|
|
|
The research demonstrated that the OX40 design enhanced the antitumor activity of CAR-T cells with the potential to overcome the challenge of treating solid tumors |
HONG KONG, Jan 29, 2021 - (ACN Newswire) - China Biotech Services Holdings Limited ("CH BIOTECH SER" or "Company", stock code: 8037.HK) non-wholly-owned subsidiary Shanghai Longyao Biotechnology Co., Ltd. ( "Shanghai Longyao"), the Chief Scientist Professor Xuanming Yang published a CD20-CART-OX40 related research article on January 27, 2021, EST, on Science Translational Medicine. Professor Yang found that an independently expressed full-length OX40 not only enhanced the cytotoxicity of CAR-T cells, it also reduced the exhaustion markers, thereby maintaining their function in immunosuppressive tumor microenvironment. In mouse tumor models and in patients with metastatic lymphoma, these CAR-T cells exhibited robust amplification and antitumor activities. The findings provide an alternative option for CAR-T optimization with the potential to overcome the challenge of treating solid tumors.
LY007 Cellular Injection is a chimeric antigen receptor T-cell (CAR-T) injection and is mainly used in the treatment of relapsed/refractory CD20-positive B-cell non-Hodgkin lymphoma, including diffuse large B-cell lymphoma and metastatic follicular lymphoma. LY007 Cellular Injection has been developed independently by Shanghai Longyao and incorporates its patented OX40 co-stimulatory signal design. Experiments have proved that the design enhances the efficacy of the Product without compromising safety. According to the clinical trial application of LY007 Cellular Injection, Shanghai Longyao will commence Phase I clinical trial and study of LY007 Cellular Injection based on the submitted proposal. On January 21, 2021, the National Medical Products Administration's approval of Shanghai Longyao's clinical trial application for LY007 Cellular Injection demonstrates Shanghai Longyao's capabilities in the research and development of immunocellular drugs.
For further information about the CD-20-CART-OX40 related research article of Professor Yang Xiaoming, please visit the website of Science Translational Medicine https://stm.sciencemag.org/content/13/578/eaba7308
Topic: Press release summary
Sectors: Daily Finance, Daily News, BioTech, Healthcare & Pharm
https://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
Latest Press Releases
Denmark Buys Four MQ-9B SkyGuardians From GA-ASI
July 23, 2025 22:00 HKT/SGT
|
|
|
China's Largest Agricultural Internet Company Yimutian Set to List on Nasdaq
July 23, 2025 20:03 HKT/SGT
|
|
|
U.S. Polo Assn. Celebrates Fifth Year as Official Apparel Partner for 2025 British Open Polo Championship for the Cowdray Gold Cup, Broadcast by the Sports Brand Globally on ESPN for the First Time
July 23, 2025 19:00 HKT/SGT
|
|
|
Prototype divertor outer vertical target for the ITER fusion experimental reactor is completed and the sample has passed the ITER Organization's certification test
Wednesday, July 23, 2025 12:10:00 PM
|
|
|
Sharp Exhibits at the 2nd SPEXA - International Space Business Expo
Wednesday, July 23, 2025 9:30:00 AM
|
|
|
Launch of Beova(R) Tablets in Thailand for Overactive Bladder
Wednesday, July 23, 2025 9:07:00 AM
|
|
|
Crown Bioscience San Diego Achieves CLIA Certification to Enhance Clinical Trial Support
Wednesday, July 23, 2025 9:00:00 AM
|
|
|
Peapack-Gladstone Financial Corp (NASDAQ: PGC) Second Quarter 2025 Financial Results
July 22, 2025 19:44 HKT/SGT
|
|
|
Military Metals Announces Grab Sample Results up to 40.6% Antimony and 106.5 gpt Gold from Stockpile of Historically Mined Material at West Gore Antimony-Gold Project, Nova Scotia
July 22, 2025 19:39 HKT/SGT
|
|
|
35th Hong Kong Book Fair attracts some 900,000 visits despite typhoon
July 22, 2025 19:22 HKT/SGT
|
|
|
|
More Press release >> |
|
|
|